Brief: Tricida Committed To Seeking FDA Approval For Commercialization Of Veverimer As Treatment For Metabolic Acidosis

Tricida

15/04/2020 12:26

April 15 (Reuters) - Tricida Inc  TCDA.O :
    * TRICIDA - COMMITTED TO SEEKING FDA APPROVAL, TO PREPARING
FOR
COMMERCIALIZATION OF VEVERIMER AS TREATMENT FOR METABOLIC
ACIDOSIS
    * TRICIDA - ASSESSING POTENTIAL IMPACT OF COVID-19 ON
PATIENT
RECRUITMENT INTO, AND ABILITY TO MAINTAIN PATIENTS ENROLLED IN,
VALOR-CKD TRIAL
    * TRICIDA INC - AT THIS TIME, DO NOT BELIEVE COVID-19
PANDEMIC HAS
AFFECTED VEVERIMER PDUFA GOAL DATE OF AUGUST 22, 2020
    * TRICIDA INC - AT THIS TIME, COVID-19 HAS NOT MATERIALLY
IMPACTED
OUR CURRENT FINANCIAL RESOURCES OR OUR OUTLOOK
    * TRICIDA - AT THIS TIME, HAS SUFFICIENT SUPPLY OF VEVERIMER
DRUG
SUBSTANCE TO SUPPORT FOR ABOUT 12 MONTHS SUPPLY REQUIREMENTS FOR
VALOR-CKD TRIAL
    * TRICIDA - EXPECTS CASH, CASH EQUIVALENTS, INVESTMENTS AS
OF DEC
31, 2019, ADDITIONAL BORROWING CAPACITY OF $90 MILLION UNDER
HERCULES DEBT FACILITY WILL ENABLE CO TO FUND OPERATIONS INTO H2
2021

Source : (https://bit.ly/3bcC4mu)
Further company coverage:  TCDA.O 

 ((Reuters.Briefs@thomsonreuters.com;))